v3.26.1
Collaborations, Licensing Arrangements, Other Asset Acquisitions, and Others - Narrative (Details)
¥ in Millions, $ in Millions
1 Months Ended 12 Months Ended
Jun. 17, 2026
JPY (¥)
May 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Feb. 28, 2025
USD ($)
Mar. 31, 2026
Mar. 31, 2025
USD ($)
Jun. 01, 2024
USD ($)
May 01, 2024
USD ($)
Apr. 01, 2024
USD ($)
IBI363                  
Disclosure of detailed information about intangible assets [line items]                  
Proportion of cost split in joint operation         60.00%        
Proportion of ownership interest in joint operation         60.00%        
Innovent Biologics, Inc. | IBI363                  
Disclosure of detailed information about intangible assets [line items]                  
Proportion of cost split in joint operation         40.00%        
Proportion of ownership interest in joint operation         40.00%        
Protagonist Therapeutics, Inc.                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets                 $ 300
Protagonist Therapeutics, Inc. | Protagonist, Contractual Commitments                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets, payment | ¥ ¥ 200                
AC Immune SA                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets               $ 100  
Additional potential payment, pharmaceutical asset acquisition agreement               $ 2,100  
Ascentage Pharma                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets             $ 100    
Keros Therapeutic                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets, payment       $ 200          
Innovent Biologics, Inc.                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets, payment     $ 1,200            
TAK-079 | Blackstone Life Sciences, BXLS | Maximum                  
Disclosure of detailed information about intangible assets [line items]                  
Development funding agreement, receivable       $ 300          
Additional potential payment, regulatory approval milestones           $ 415      
Additional potential payment, cumulative sales milestones           $ 500      
TAK-079 | Blackstone Life Sciences, BXLS | Maximum | Major R&D Related Agreements                  
Disclosure of detailed information about intangible assets [line items]                  
Development funding agreement, receivable   $ 550              
Development funding agreement, increase (decrease) in receivable   $ 250